Project Grant R01CA296006
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $728K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $487,902 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct genome-wide association studies interrogating cancer pleiotropy and shared genetic susceptibility mechanisms across multiple cancer types. The project leverages existing genomic data from large biobanks including the UK Biobank and All of Us to identify shared germline susceptibility regions underlying cancer risk. The...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...
- The National Cancer Institute of the Department of Health and Human Services awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $543,757 on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate gut microbiota-driven tuft-2 cell expansion as a biomarker for aggressive adenoma formation in early-onset colorectal cancer among Black US residents. The project tests the hypothesis that gut microbiota from early-onset colorectal...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $660,541 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer. The research addresses the spatial and cellular interactions between Fusobacterium nucleatum (FN), a bacterium enriched in colorectal cancer tissues and associated with disease recurrence and...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $692,368 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the MYC transcription factor network and its role in oncogenic and tumor-suppressive pathways. The research examines how dysregulation of MYC family transcription factors drives cancer initiation, progression, immune escape, and chemoresistance. The project uses genetically engineered...
- The National Cancer Institute awarded $467,261 to Hackensack University Medical Center on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate myeloid phagocyte activation by commensal-activated complement C5AR1 signaling in colorectal cancer. The research examines how tumor-associated microbes—specifically Candida albicans and Fusobacterium nucleatum, two microorganisms enriched in colorectal cancer—amplify C5AR1 signaling to shape the tumor...
- The National Institutes of Health National Cancer Institute awarded $689,865 to The Trustees of Columbia University in the City of New York on August 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop methodological tools and frameworks for cancer microbiome study design and analysis. The award funds development of a comprehensive toolset to address contamination and batch-effect challenges in tumor microbiome research. Specific deliverables include a new method to...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $760,396 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate metabolomic mechanisms contributing to prostate cancer risk across multiple populations. The research will generate circulating metabolomic data on 3,006 prostate cancer cases and 3,006 controls from Black, Hispanic, Japanese American, and White individuals enrolled in the Multiethnic...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $439,639 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop methods for microsimulation model calibration that inform cancer screening policy and guidelines. The project will create a flexible, publicly available tool for model calibration; develop a framework and tools for evaluating calibration methods; and produce guidelines for model calibration. Microsimulation modeling projects...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $737,945 on May 4, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop quantitative measurement tools for assessing provider and intervention characteristic determinants of evidence-based cancer care implementation. The project addresses critical gaps in implementation science by using item response theory to create flexible, tailorable quantitative measures of intervention and provider...